BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 16632420)

  • 1. Cell signalling: growth factors and tyrosine kinase receptors.
    Perona R
    Clin Transl Oncol; 2006 Feb; 8(2):77-82. PubMed ID: 16632420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinases as targets in cancer therapy - successes and failures.
    Traxler P
    Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
    Anderson NG; Ahmad T
    Front Biosci; 2002 Sep; 7():d1926-40. PubMed ID: 12161338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.
    Hamid O
    J Am Pharm Assoc (2003); 2004; 44(1):52-8. PubMed ID: 14965154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
    Pietras K; Pahler J; Bergers G; Hanahan D
    PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).
    Gaumann AK; Drexler HC; Lang SA; Stoeltzing O; Diermeier-Daucher S; Buchdunger E; Wood J; Bold G; Breier G
    Int J Oncol; 2014 Dec; 45(6):2267-77. PubMed ID: 25340839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
    Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
    Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-epidermal growth factor receptor strategies for advanced breast cancer.
    Campos SM
    Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311
    [No Abstract]   [Full Text] [Related]  

  • 11. PDGF receptors as targets in tumor treatment.
    Ostman A; Heldin CH
    Adv Cancer Res; 2007; 97():247-74. PubMed ID: 17419949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the HER-kinase axis in cancer.
    Gross ME; Shazer RL; Agus DB
    Semin Oncol; 2004 Feb; 31(1 Suppl 3):9-20. PubMed ID: 15052539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
    Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
    Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB/HER receptor family in breast cancer--the more we search the more we learn.
    Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
    Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136
    [No Abstract]   [Full Text] [Related]  

  • 15. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
    Sennino B; Kuhnert F; Tabruyn SP; Mancuso MR; Hu-Lowe DD; Kuo CJ; McDonald DM
    Cancer Res; 2009 May; 69(10):4527-36. PubMed ID: 19401451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF receptor signaling in tumor angiogenesis.
    McMahon G
    Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.
    Grant S; Qiao L; Dent P
    Front Biosci; 2002 Feb; 7():d376-89. PubMed ID: 11815285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling.
    Eccles SA
    Recent Results Cancer Res; 2000; 157():41-54. PubMed ID: 10857161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor receptors: expression and function in solid tumors.
    Wey JS; Stoeltzing O; Ellis LM
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.